Pharmaceuticals & Biotech/Lifesciences

FNArena Windows (Sectors)

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

The New Criterion’s Tim Boreham highlights Arovella Therapeutics in a struggling cell therapies sector worldwide

Aug 29 2024

Sleep treatment leader ResMed has faced a number of headwinds but has surprised analysts with a strong improvement in gross margins

Aug 07 2024


ASX CODE COMPANY NAME LAST PRICE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET
ARX AROA BIOSURGERY LIMITED $0.60 $0.87 $0.44 108.7

$0.975

AVH AVITA MEDICAL INC $3.03 $5.62 $2.34

$4.52

BIO AVITA MEDICAL INC $0.80 $0.87 $0.11

$0.85

CSL CSL LIMITED $281.62 $313.55 $246.55 27.5

$335.125

CUV CSL LIMITED $13.73 $18.20 $12.96

$19.083

GSS GENETIC SIGNATURES LIMITED $0.72 $xx.xx $xx.xx xx.x xx.xx
IMM IMMUTEP LIMITED $0.28 $xx.xx $xx.xx xx.x xx.xx
IMU IMMUTEP LIMITED $0.05 $xx.xx $xx.xx xx.x xx.xx
MAP MICROBA LIFE SCIENCES LIMITED $0.17 $xx.xx $xx.xx xx.x xx.xx
MSB MESOBLAST LIMITED $1.31 $xx.xx $xx.xx xx.x xx.xx
NEU NEUREN PHARMACEUTICALS LIMITED $12.25 $xx.xx $xx.xx xx.x xx.xx
OPT NEUREN PHARMACEUTICALS LIMITED $0.80 $xx.xx $xx.xx xx.x xx.xx
PAR PARADIGM BIOPHARMACEUTICALS LIMITED $0.21 $xx.xx $xx.xx xx.x xx.xx
PER PERCHERON THERAPEUTICS LIMITED $0.08 $xx.xx $xx.xx xx.x xx.xx
PNV POLYNOVO LIMITED $2.02 $xx.xx $xx.xx xx.x xx.xx
PYC PYC THERAPEUTICS LIMITED $0.19 $xx.xx $xx.xx xx.x xx.xx
TLX TELIX PHARMACEUTICALS LIMITED $21.45 $xx.xx $xx.xx xx.x xx.xx
Previous Stories
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024

Tim Boreham revisits the investment case and corporate developments for Aroa Biosurgery


CSL Shares Breaking Free

Jul 23 2024

Michael Gable of Fairmont Equities observes CSL shares are breaking through a ceiling that has held for four years, suggesting major upside potential


Dr Boreham’s Crucible: SDI

Jul 19 2024

The New Criterion’s Tim Boreham shines the light on family-run dental products manufacturer SDI (Formerly Southern Dental Industries)


‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024

New research on the Pharmaceutical Wholesaling sector identifies three stocks with long-term defensive growth within an improving government funding framework


Twists And Turns Of Telix And Australian Biotech

Jul 10 2024

In the wake of Telix Pharmaceuticals’ non-IPO on the Nasdaq, FNArena shines a light on the company’s fortunes and that of Australian biotech and cancer research generally


Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024

The New Criterion’s Tim Boreham explains the how and why behind Radiopharm Theranostics’ latest capital raising


Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024

The next twelve months could be exciting for Dengue fever solutions seeker Island Therapeutics, the New Criterion’s Tim Boreham reports


Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024

Amplia Therapeutics is in pursuit of a cancer drug for pancreatic cancer and possibly other indications including ovarian cancer, the New Criterion’s Tim Boreham reports


Is The Long Wait For CSL About To End?

May 30 2024

The Chartist reports it looks like CSL shares might be ready to leave the past four-year pause in the past


Dr Boreham’s Crucible: Invion

May 13 2024

As per the New Criterion’s Tim Boreham, Invion is an old company on a new mission